These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 7344512)

  • 21. Molecular analysis of the in vivo metabolism and biodistribution of metabolically and non-metabolically activated combi-molecules of the triazene class.
    Qiu Q; Larroque AL; Gibbs B; Fang Y; Lakhrissi Y; Soucy JP; Mzengeza S; Rachid Z; Jean-Claude BJ
    Drug Metab Lett; 2009 Jan; 3(1):1-9. PubMed ID: 19356110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proceedings: Tumour inhibitory triazenes.
    Wilman DE
    Br J Cancer; 1975 Aug; 32(2):246. PubMed ID: 1212368
    [No Abstract]   [Full Text] [Related]  

  • 23. Microsomal metabolism of triazenylimidazoles.
    Hill DL
    Cancer Res; 1975 Nov; 35(11 Pt 1):3106-10. PubMed ID: 241485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutagenic and alkylating activities of 3-methyl-1-phenyltriazenes and their possible role as carcinogenic metabolites of the parent dimethyl compounds.
    Malaveille C; Brun G; Kolar G; Bartsch H
    Cancer Res; 1982 Apr; 42(4):1446-53. PubMed ID: 7060018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microsomal mediated metabolism of dialkylaryltriazenes. I. Demethylation of ring halogenated 3,3-dimethyl-1-phenyltriazenes.
    Pool BL
    J Cancer Res Clin Oncol; 1979 Apr; 93(3):215-20. PubMed ID: 468884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour inhibitory triazenes: structural requirements for an active metabolite.
    Connors TA; Goddard PM; Merai K; Ross WC; Wilman DE
    Biochem Pharmacol; 1976 Feb; 25(3):241-6. PubMed ID: 1267820
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparative metabolism and carcinogenicity of ring-halogenated 3,3-dimethyl-1-phenyltriazenes.
    Kolar GF; Habs M
    J Cancer Res Clin Oncol; 1984; 108(1):71-5. PubMed ID: 6746720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolism of the anticancer agent 1-(4-acetylphenyl)-3,3-dimethyltriazene.
    Farina P; Benfenati E; Reginato R; Torti L; D'Incalci M; Threadgill MD; Gescher A
    Biomed Mass Spectrom; 1983 Aug; 10(8):485-8. PubMed ID: 6616025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Some aspects of metabolic activation of chemical carcinogens in relation to their organ specificity.
    Bartsch H; Margison GP; Malaveille C; Camus AM; Brun G; Margison JM; Kolar GF; Wiessler M
    Arch Toxicol; 1977 Dec; 39(1-2):51-63. PubMed ID: 579982
    [No Abstract]   [Full Text] [Related]  

  • 30. Sex differences in in-vitro activation and in-vivo carcinogenicity.
    Matsushima T; Araki A; Muramatsu M; Kobayashi K; Okagawa K; Kosaki G
    IARC Sci Publ; 1983; (51):141-6. PubMed ID: 6365766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro biotransformation of carbinolamine metabolites of cytotoxic dimethyltriazenes [proceedings].
    Gescher A; Hickman JA; Stevens MF
    Br J Pharmacol; 1979 Jul; 66(3):434P-435P. PubMed ID: 526723
    [No Abstract]   [Full Text] [Related]  

  • 32. [Carcinostatics based on 1-phenyl-3,3-dimethyltriazene. Contribution on their metabolism].
    Rambousek V; Zvĕrina V; Matrka M
    Cesk Farm; 1978 Dec; 27(10):438-41. PubMed ID: 752419
    [No Abstract]   [Full Text] [Related]  

  • 33. [Post- and prenatal induction of nervous system tumors in rats by phenyl-dimethyl-triazene].
    Schneider J; Warzok R; Schreiber D
    Zentralbl Allg Pathol; 1972; 115(1):8-12. PubMed ID: 4337690
    [No Abstract]   [Full Text] [Related]  

  • 34. Absorption, metabolism, and disposition of 1,3-diphenyl-1-triazene in rats and mice after oral, i.v., and dermal administration.
    Mathews JM; De Costa KS
    Drug Metab Dispos; 1999 Dec; 27(12):1499-504. PubMed ID: 10570033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activation of dacarbazine (DTIC) for a human tumor cloning system.
    Metelmann HR; Von Hoff DD
    Int J Cell Cloning; 1983 Apr; 1(1):24-32. PubMed ID: 6674387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of action and pharmacology studies with DTIC (NSC-45388).
    Loo TL; Housholder GE; Gerulath AH; Saunders PH; Farquhar D
    Cancer Treat Rep; 1976 Feb; 60(2):149-52. PubMed ID: 1260772
    [No Abstract]   [Full Text] [Related]  

  • 37. [Relationship between immunosuppressive and therapeutic effects of selected cytostatics under experimental conditions].
    Markowska-Woyciechowska A
    Patol Pol; 1983; 34(4):391-404. PubMed ID: 6677862
    [No Abstract]   [Full Text] [Related]  

  • 38. Antimetastatic action of a new analog of dacarbazine in mice bearing Lewis lung carcinoma.
    Perissin L; Facchin P; Bedini A; Diamantini G; Tontini A; Tarzia G
    Anticancer Res; 2000; 20(3A):1513-7. PubMed ID: 10928064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biotransformation and quantitative determination of sulfur-containing metabolites of 1,4-dibromobutane in the rat.
    Onkenhout W; van Loon WM; Buijs W; van der Gen A; Vermeulen NP
    Drug Metab Dispos; 1986; 14(5):608-12. PubMed ID: 2876869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Additional pathway of the metabolic activation of N-nitrosodiethylamine in the rat liver].
    Khripach LV; Shuliakovskaia TS; Loknitskaia NN; Fonshteĭn LM
    Eksp Onkol; 1987; 9(2):46-9. PubMed ID: 3582239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.